CMC has entered into an agreement with Symphogen A/S for process development and cGMP manufacture.08-Aug-2008COPENHAGEN, DENMARK; August 05, 2008CMC Biologics A/S announced today that it has entered into an agreement with Symphogen A/S for process development and cGMP manufacture of an undisclosed polyclonal antibody product candidate... Acorda Therapeutics, Inc. Signs GGF2 Manufacturing Agreement with CMC ICOS Biologics, Inc.09-Apr-2008HAWTHORNE, NY and COPENHAGEN, DENMARK – April 9, 2008Acorda Therapeutics, Inc. (NASDAQ: ACOR) and CMC ICOS Biologics. Inc. today announced that Acorda has selected CMC ICOS as the contract manufacturer for GGF2, the lead molecule... Raven biotechnologies advances RAV18 through agreement with CMC ICOS Biologics Inc.12-Mar-2008South San Francisco, CA and Seattle, WA. March 12 2008. Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer and CMC ICOS... CMC Biopharmaceuticals A/S has changed its name to CMC Biologics A/S01-Mar-2008Copenhagen, Denmark. March, 2008. CMC Biopharmaceutical A/S is changing its name to CMC Biologics A/S with immediate effect. There are no other changes. We continue to operate from the same address in Copenhagen and e-mail... CMC Biologics has closed a share capital offering in connection with its acquisition of ICOS Biologics Manufacturing.28-Feb-2008COPENHAGEN, Denmark , 28th February, 2008 CMC Biologics A/S (CMC, formerly CMC Biopharmaceuticals A/S) announced today that it has closed a share capital offering which was arranged as part of the Company’s financial strategy in... |  | |